ArticleAmerican journal of hematology2020

Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.

Frank Richard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.